Apeiron Biologics is a pioneering biotechnology company focused on transforming cancer treatment through innovative immunotherapy solutions. The company achieved a significant milestone in 2017 with the market approval of its cancer drug Qarziba®, which is now licensed to EUSAPharma. This product exemplifies Apeiron's commitment to developing therapies that not only target cancer cells but also enhance the body's immune response, thereby aiming to improve patient outcomes and reduce the fear associated with cancer diagnosis and treatment.

In addition to its flagship product, Apeiron Biologics has established a robust research and development portfolio, which is managed by its wholly-owned subsidiary, invIOs. This subsidiary is dedicated to advancing the company's innovative approaches to cancer treatment, focusing on harnessing the immune system to combat various forms of cancer. Through its ongoing research efforts, Apeiron aims to expand its pipeline of immunotherapeutic products, further solidifying its position as a leader in the field of cancer biotechnology.

Austria

APEIRON is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies.A drug candidate developed by APEIRON Biologics named APN01 is being tested in China in a phase one pilot trial as a treatment for Covid-19. APN01 is based on research conducted by a professor at the University of British Columbia for treating SARS. The research revealed that the ACE2 protein was the main receptor for the SARS virus.

Apeiron Biologics

Company Details